Modality
Vaccine
MOA
CDK2i
Target
CD38
Pathway
STING
AngelmanPNHGA
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Sep 2031
Phase 2Current
NCT03620071
1,423 pts·GA
2018-02→2031-09·Active
NCT04854579
2,761 pts·GA
2023-03→2025-11·Terminated
4,184 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-105mo agoPh2 Data· GA
2031-09-285.5y awayPh2 Data· GA
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Active
P2
Termina…
Catalysts
Ph2 Data
2025-11-10 · 5mo ago
GA
Ph2 Data
2031-09-28 · 5.5y away
GA
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03620071 | Phase 2 | GA | Active | 1423 | HAM-D |
| NCT04854579 | Phase 2 | GA | Terminated | 2761 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R |